Skip to main content
SpringerLink
Log in
Book cover

Therapie innerer Krankheiten pp 32–57Cite as

Kardiomyopathien

  • Chapter

  • 20 Accesses

Zusammenfassung

In der älteren Literatur wurden Kardiomyopathien als „Erkrankungen des Herzmuskels unklarer Ätiologie“ definiert und von spezifischen Herzmuskelerkrankungen bekannter Ätiologie abgegrenzt. Entsprechend ihrer charakteristischen anatomischen Veränderungen, unterschiedlicher klinischer Verläufe und variierender zur Erkrankung führender und diese unterhaltender pathophysiologischer Mechanismen wurden sie in dilatative, hypertrophe, restriktive und nicht klassifizierbare Kardiomyopathien eingeteilt.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abelmann W, Lorell B (1989) The challenge of cardiomyopathy. J Am Coll Cardiol 13: 1219–1239

    Article  PubMed  CAS  Google Scholar 

  2. Adams KF, Gheorghiade M, Uretsky BF,Young JB, Ahmed S, Tomasko L, Packer M (1997) Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 30: 42–48

    Google Scholar 

  3. Amidon TM, Parmley W (1994) Is there a role of positive inotropic agents in congestive heart failure: Focus on mortality. Clin Cardio l 17: 641–647

    Google Scholar 

  4. Auricchio A, Sommariva L, Salo RW, Scafuri A, Chiariello L (1993) Improvement of cardiac function in patients with severe congestive heart failure and coronary artery disease by dual chamber pacing with shortened AV-delay. PACE 16: 2034–2043

    Google Scholar 

  5. Badorff C, Noutsias M, Kühl U, Schultheiss HP (1997) Cell-mediated cytotoxicity in hearts with dilated cardiomypathy: Correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol 29: 429-434

    Google Scholar 

  6. Badorff C, Schwimmbeck PL, Kühl U, Gerhold M, Stein H, Schultheiss HP (1997) Kardiale Sarkoidose: Diagnosesicherung durch Endomyokardbiopsie and Therapie mit Kortikosteroiden. Z Kardiol 86: 9–14

    Article  PubMed  CAS  Google Scholar 

  7. Billingham M (1987) Acute myocarditis: a diagnostic dilemma. Br Heart J 58: 6–8

    Article  PubMed  CAS  Google Scholar 

  8. Blanc JJ, Etienne Y, Gilard M, Mansourati J, Munier S, Boschat J, Benditt DG, Lurie KG (1997) Evaluation of different ventricular pacing sites in patients with severe heart failure. Results of an acute hemodynamic study. Circulation 96: 3273–3277

    Article  PubMed  CAS  Google Scholar 

  9. Brecker SJD, Xiao HB, Sparrow J, Gibson DG (1992) Effects of dual-chamber pacing with short AV-delay in dilated cardiomyopathy. Lancet 340: 1308–1312

    Article  PubMed  CAS  Google Scholar 

  10. Brown NJ, Vaughan DE (1998) Angiotensin-converting enzyme inhibitors. Circulation 97: 1411–1420

    Article  PubMed  CAS  Google Scholar 

  11. Burke AP, Farb A, Tashko G, Virmani R (1998) Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium. Are they different diseases? Circulation 97: 1571–1580

    Article  PubMed  CAS  Google Scholar 

  12. Camerini F, Salvi A, Bussani R, Dreas L, DiLenarda A, 31. Hrovatin E, Sinagra G, Silvestri F (1988) Immunosuppressive treatment in myocarditis. In: Schulheiss HP (ed) New concepts in viral heart disease. Virology, immunology and clinical management. Springer, Berlin Heidelberg New 32. York Tokyo, pp 402–425

    Chapter  Google Scholar 

  13. Cody RJ (1988) Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? J Am Coll Cardiol 12: 559–569

    Article  PubMed  CAS  Google Scholar 

  14. Cohn JN (1989) Inotropic therapy for heart failure. N Engl J Med 320: 729–731

    Article  PubMed  CAS  Google Scholar 

  15. Cohn JN, Archibald DG, Ziesche S et al. (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Adminsitraiton Co- 35. operative Study. N Engl J Med 314: 1547–1552

    Article  PubMed  CAS  Google Scholar 

  16. Cold MR, Feliciano Z, Gottlieb SS, Fisher ML (1995) Dual-chamber pacing with short atrioventricular delay in con- 36. gestive heart failure: a randomized study. J Am Coll Cardiol 26: 967–973

    Google Scholar 

  17. Cyclosporine A (CyA) for successful treatment of myocarditis. Eur Heart J 7:452

    Google Scholar 

  18. Daubert JC (1996) Pacing and hypertrophie cardiomyopathy. PACE 19: 1141–1142

    Article  PubMed  CAS  Google Scholar 

  19. De Marco T, Chatterjee K (1998) Phosphodiesterase inhibitors in refractory heart failure: Bridge to beta-blockade? J Am Coll Cardiol 31: 1341–1343

    Google Scholar 

  20. Dec GW jr, Palacios IF, Fallon JT, Aretz HTh, Mills J, Lee DC-S, Johnson RA (1985) Active myocarditis in the spectrum of acute dilated cardiomyopathies. N Engl J Med 312: 885–890

    Article  Google Scholar 

  21. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, 41. Wright R, for the Milrinone Multicenter Trial Group (1989): A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320: 677–683

    Google Scholar 

  22. Ettinger J, Feucht H, Gärtner R, Kotzur J, Schlag R, Gokel JM, Jahrmärker H (1986) Cyclosporine A (CyA) for successful treatment of myocarditis. Europ Heart J 7: 452

    CAS  Google Scholar 

  23. Fallon JT (1987) Myocarditis and dilated cardiomyopathy: different stages of the same disease? In: Waller B (ed) Contemporary issues in cardiovascular pathology. Cardiovasc Clin 18: 155–162

    Google Scholar 

  24. Fananapazir L, Cannon ROI, Triopdi D, Panza J (1992) Impact of dual-chamber permenent pacing in patients with hypertrophic obstructive cardiomyopathy with sym ptoms refractory to verapamil and beta-adrenergic blocker therapy. Ciruculation 85: 2149–2161

    Article  CAS  Google Scholar 

  25. Fananapazir L, Epstein ND, Panza A, Curiel R, Tripodi D, McAreavey D (1994) Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 90: 2731–2742

    Google Scholar 

  26. Fananapazir L, Tripody D, McAreavey D (1998) Five-year results of dual chamber pacing in obstructive hypertrophic cardiomyopathy patients with severe symptoms (abstracts). PACE 21: 791

    Google Scholar 

  27. Fontaine G, Fontaliran F, Frank R (1998) Arrhythmogenic right ventricular cardiomyopathies. Clinical forms and main differential diagnosis. Circulation 97: 1532–1535

    Article  PubMed  CAS  Google Scholar 

  28. Gadler F, Linde C, Juhlin-Dannfelt A, Ribeiro A, Rydén L (1997) Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. Eur Heart J 18: 636–642 51.

    Article  Google Scholar 

  29. Gras D, Mabo P, de Place C, Metali P, Le Breton H, Daubert C (1995) Regressioin of mitral regurgitation with DDD pacing in hypertrophic obstructive cardiomyopathy (abstract). PACE 18: 1784

    Google Scholar 

  30. Grötz J (1987) Medikamentös-toxisch bedingte Herzmuskelerkrankungen. Dtsch Med Wochenschr 112: 691–695

    Article  PubMed  Google Scholar 

  31. Heidenreich PA, Lee TT, Massie BM (1997) Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 30: 27–34

    Article  PubMed  CAS  Google Scholar 

  32. Hochleitner M, Hörtnagl H, Fridrich L, Gschnitzer F (1992) Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy. Am J Cardiol 70: 1320–1325

    Article  PubMed  CAS  Google Scholar 

  33. Homans DC (1985) Peripartum cardiomyopathy. N Engl J Med 312: 1432–1437

    Article  PubMed  CAS  Google Scholar 

  34. Hunt SA, Frazier OH (1998) Mechanical circulatory support and cardiac transplantation. Circulation 97: 2079–2090

    Article  PubMed  CAS  Google Scholar 

  35. Johnson RA, Palacios (1982) Dilated cardiomyopathies of the adult (second of two parts). N Engl J Med 307: 1119–1126

    Article  PubMed  CAS  Google Scholar 

  36. Johnson RA, Palacios I (1982) Dilated cardiomyopathies of the adult (first of two parts). N Engl J Med 307: 1051–1058

    Article  PubMed  CAS  Google Scholar 

  37. Kereiakes DJ, Parmley WW (1984) Myocarditis and cardiomyopathy. Am Heart J 108: 1318–1326

    Google Scholar 

  38. Kizilbash AM, Heinle SK, Grayburn PA (1998) Spontaneaous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 97: 461–466

    Article  PubMed  CAS  Google Scholar 

  39. Koniaris LS, Goldhaber SZ (1998) Anticoagulation in dilated cardiomyopathy. J Am Coll Cardioo131: 745–748

    Google Scholar 

  40. Kühl U, Noutsias M, Seeberg B, Schultheiss HP (1996) Immunohistological evidence for a chronic intramyocardial imflammatory process in dilated cardiomyopathy. Heart 75: 295–300

    Article  PubMed  Google Scholar 

  41. Kühl U, Pauschinger M, Schultheiss HP (1997) Neue Konzepte zur Diagnostik der entzündlichen Herzmuskelerkrankung. Dtsch med Wschr 122: 690–698

    Article  PubMed  Google Scholar 

  42. Kühl U, Pauschinger, Schultheiss HP (1997) Äthiopathogenetische Differenzierung der entzündlichen Kardiomyopathie. Internist 38: 590–601

    Article  PubMed  Google Scholar 

  43. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM (1989) Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 117: 876

    Article  PubMed  CAS  Google Scholar 

  44. Lauer B, Niederau C, Kühl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP (1997) Cardiac Troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30: 1354–1359

    Article  PubMed  CAS  Google Scholar 

  45. Linde C, Gadler F, Edner M, Nordlander R, Rosenqvist M, Rydén L (1995) Results of atrioventricular synchronous pacing with optimized delay in patients with severe congestive heart failure. Am J Cardiol 75: 919–923

    Google Scholar 

  46. Massie BM, Shah NB (1995) Future approaches to pharmacologic therapy for congestive heart failure. Curr Opinion Cardiol 10: 229–237

    Google Scholar 

  47. Midei MG, DeMent SH, Feldmann AM, Hutchins GM, Baughman KL (1990) Peripartum myocarditis and cardiomyopathy. Circulation 81: 922–928

    Article  PubMed  CAS  Google Scholar 

  48. Myerburg RJ, Castellanos A (1997) Clinical trials of implantable defibrillators. N Engl J Med 337:1621–1623 Newman LS, Rose CS, Maier LA (1997) Sarcoidosis. N Engl J Med 336: 1224–1234

    Google Scholar 

  49. Newman LS, Rose CS, Maier LA (1997) Sarcoidosis. N Engl J Med 336: 1224–1234

    Article  CAS  Google Scholar 

  50. O’Connel JB, Dec GW, Mason JW (1988) The role of cardiac transplantation in patients with active myocarditis. In: Schultheiss HP (ed) New concepts in viral heart disease. Virology, immunology and clinical management. Springer, Berlin Heidelberg New York Tokyo, pp 426–432

    Chapter  Google Scholar 

  51. O’Connel JB, Mason JW (1989) Therapeutic implications of immune mechanisms in myocarditis. Semin Immunopathol 11: 43–49

    Google Scholar 

  52. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355

    Google Scholar 

  53. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, Schaer GL et al. (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321: 1061–1068

    Article  PubMed  CAS  Google Scholar 

  54. Pauschinger M, Kühl U, Dörner A, Schieferecke K et al. (1998) Nachweis enteroviraler RNA in endomyokardialen Biopsien bei inflammatorischer Kardiomyopathie und idiopathischer dilatativer Kardiomyopathie. Z Kardiol 87: 443–452

    Google Scholar 

  55. Pfeffer MA, Stevenson LW (1996) /3-adrenergic blockers and survival in heart failure. N Engl J Med 334:1396-1397

    Google Scholar 

  56. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 349: 747–752

    Article  PubMed  CAS  Google Scholar 

  57. Raifer SI, Rossen JD, Nemanich JW, Douglas FL, Davis F, Osinski J (1987) Sustained hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines. J Am Coll Cardiol 10: 1286–1293

    Article  Google Scholar 

  58. Schulte HD, Lösse B (1985) Hyperthrophische Kardiomyopathie: chirurgische Behandlung und Ergebnisse. Herz 10: 102–108

    PubMed  CAS  Google Scholar 

  59. Schultheiss HP, Schwimmbeck P (eds) (1996) The role of Immune Mechanisms in cardiovascular disease. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  60. Schultheiss HP, Kühl U, Janda I, Melzner B, Ulrich G, Morad M (1988) Antibody-mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 168: 2105–2119

    Article  PubMed  CAS  Google Scholar 

  61. Schultheiss HP, Pauschinger M, Kühl U (1998) Pathogenese der entzündlichen Kardiomyopathie. Med Klin 93:229–235

    Google Scholar 

  62. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31: 252–258

    Article  PubMed  CAS  Google Scholar 

  63. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowers BD, Zisman LS, Ferguson DA, Bristow MR (1998) Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 31: 1336–1340

    Google Scholar 

  64. Shanes JG (1987) /3-Blockade - rational or irrational therapy for congestive heart failure? Ciruclation 76: 971–973

    Google Scholar 

  65. Sigwart U (1995) Non-surgical myocardial reduction of bypertrophic obstructive cardiomyopathy. Lancet 346: 211–214

    Google Scholar 

  66. Slade AKB, Sadoul N, Shapiro L et al. (1996) DDD pacing in hypertrophic cardiomyopathy, a multicenter clinical experience. Heart 75: 44–49

    Article  PubMed  CAS  Google Scholar 

  67. Spirito P, Seidmann CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336: 775–785

    Article  PubMed  CAS  Google Scholar 

  68. The Captopril-Digoxin Multicenter Research Group (1988) Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 59: 539–544

    Google Scholar 

  69. The Consensus Trial Study Group (1987) The effects of enalapril on mortality in severe congestive heart failure: Results of the co-operative North Scandinavian enalapril survival study. N Engl J Med 316: 1429–1434

    Article  Google Scholar 

  70. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533

    Article  Google Scholar 

  71. The German and Austrian XAMOTEROL Study Group (1988) Double-blind placebe-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet I: 489–493

    Google Scholar 

  72. Udelson JE, VBonow RO, O’Gara PT, Maron BJ, Van Lingen A, Bacharach SL, Epstein SE (1989) Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 79: 1052–1060

    Article  PubMed  CAS  Google Scholar 

  73. Uretsky BF, Sheahan RG (1997) Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking? J Am Coll Cardiol 3 0:1589–1597

    Google Scholar 

  74. Waagsein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A (1989) Long-term /3-blockade in dilated cardiomyopathy. Effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 8o:551–563

    Google Scholar 

  75. WHO (1980) JSFC Task force. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 44: 672–673

    Article  Google Scholar 

  76. WHO (1996) Report of the 1995 World Health Organzation/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 93: 841–842

    Article  Google Scholar 

  77. Xamoterol (1989) Stabilisierung des kardialen /3-Rezeptors? Lancet I:343–345 (Erstveröffentlichung in Englisch: Lancet 1988/II:1401–14oz)

    Google Scholar 

  78. Yee KM, Struthers AD (1997) Can drug effects on mortality in heart failure be predicted by any surrogate measure? Europ Heart J 18: 1860–1864

    Article  CAS  Google Scholar 

  79. Zee-Chen CS, Tsai CC, Palmer DC, Codd JE, Pennington DG, Williams GA (1984) High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy. J Am Coll Cardio l 3: 63–70

    Google Scholar 

Download references

Authors
  1. H.-P. Schultheiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik und Poliklinik II Klinikum Großhadern, Ludwig-Maximilians-Universität München, Marchioninistraße 15, D-81377, München, Deutschland

    Gustav Paumgartner

  2. Neurologische Klinik und Poliklinik, Universität München Klinikum Großhadern, Marchioninistraße 15, D-81377, München, Deutschland

    Th. Brandt

  3. Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, D-20246, Hamburg, Deutschland

    H. Greten

  4. Abteilung für Nephrologie Zentrum Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, D-30625, Hannover, Deutschland

    K. M. Koch

  5. Krankenhaus Zehlendorf Pneumologie I, Am Heckeshorn 33, D-14109, Berlin, Deutschland

    H. Lode

  6. Medizinische Universitätsklinik, Innere Medizin A, Albert-Schweitzer-Straße 33, D-48149, Münster, Deutschland

    J. van de Loo

  7. Medizinische Poliklinik, Universität München, Pettenkoferstraße 8a, D-80336, München, Deutschland

    M. Schattenkirchner

  8. Medizinische Klinik II, Universität Gießen, Klinikstraße 36, D-35392, Gießen, Deutschland

    W. Seeger

  9. Medizinische Klinik und Poliklinik I Klinikum Großhadern, Ludwig-Maximilians-Universität München, Marchioninistraße 15, D-81377, München, Deutschland

    G. Steinbeck

  10. Medizinische Klinik und Poliklinik, Universität Heidelberg, Bergheimer Straße 58, D-69115, Heidelberg, Deutschland

    R. Ziegler

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schultheiss, HP. (1999). Kardiomyopathien. In: Paumgartner, G., et al. Therapie innerer Krankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10477-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10477-4_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10478-1

  • Online ISBN: 978-3-662-10477-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation